TCR2 THERAPEUTICS INC (TCRR) Fundamental Analysis & Valuation

NASDAQ:TCRR • US87808K1060

Current stock price

1.48 USD
-0.09 (-5.73%)
At close:
1.53 USD
+0.05 (+3.38%)
After Hours:

This TCRR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. TCRR Profitability Analysis

1.1 Basic Checks

  • In the past year TCRR has reported negative net income.
  • TCRR had a negative operating cash flow in the past year.
TCRR Yearly Net Income VS EBIT VS OCF VS FCFTCRR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • TCRR has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCRR Yearly ROA, ROE, ROICTCRR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TCRR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRR Yearly Profit, Operating, Gross MarginsTCRR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TCRR Health Analysis

2.1 Basic Checks

  • TCRR has more shares outstanding than it did 1 year ago.
  • TCRR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCRR Yearly Shares OutstandingTCRR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
TCRR Yearly Total Debt VS Total AssetsTCRR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -6.44, we must say that TCRR is in the distress zone and has some risk of bankruptcy.
  • TCRR's Altman-Z score of -6.44 is on the low side compared to the rest of the industry. TCRR is outperformed by 70.08% of its industry peers.
  • TCRR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.44
ROIC/WACCN/A
WACCN/A
TCRR Yearly LT Debt VS Equity VS FCFTCRR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

  • TCRR has a Current Ratio of 2.96. This indicates that TCRR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.96, TCRR is doing worse than 69.28% of the companies in the same industry.
  • A Quick Ratio of 2.96 indicates that TCRR has no problem at all paying its short term obligations.
  • TCRR has a worse Quick ratio (2.96) than 68.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
TCRR Yearly Current Assets VS Current LiabilitesTCRR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TCRR Growth Analysis

3.1 Past

  • The earnings per share for TCRR have decreased strongly by -49.47% in the last year.
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.12% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRR Yearly Revenue VS EstimatesTCRR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 100M 200M 300M
TCRR Yearly EPS VS EstimatesTCRR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. TCRR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TCRR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRR Price Earnings VS Forward Price EarningsTCRR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRR Per share dataTCRR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • TCRR's earnings are expected to grow with 17.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.45%
EPS Next 3Y17.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TCRR Dividend Analysis

5.1 Amount

  • No dividends for TCRR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TCRR Fundamentals: All Metrics, Ratios and Statistics

TCR2 THERAPEUTICS INC

NASDAQ:TCRR (5/31/2023, 8:00:02 PM)

After market: 1.53 +0.05 (+3.38%)

1.48

-0.09 (-5.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11
Earnings (Next)08-07
Inst Owners0%
Inst Owner Change0%
Ins Owners9.57%
Ins Owner Change0%
Market Cap58.11M
Revenue(TTM)N/A
Net Income(TTM)-163.10M
Analysts73.33
Price Target5.86 (295.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.94%
Min EPS beat(2)-93.38%
Max EPS beat(2)-48.5%
EPS beat(4)1
Avg EPS beat(4)-34.1%
Min EPS beat(4)-93.38%
Max EPS beat(4)7.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.37%
PT rev (3m)-41.98%
EPS NQ rev (1m)-34.75%
EPS NQ rev (3m)0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-4.2
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-3.16
FCFYN/A
OCF(TTM)-2.81
OCFYN/A
SpS0
BVpS2.58
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 461.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -6.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)454.2%
Cap/Depr(5y)411.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-81.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.19%
OCF growth 3YN/A
OCF growth 5YN/A

TCR2 THERAPEUTICS INC / TCRR Fundamental Analysis FAQ

What is the fundamental rating for TCRR stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRR.


What is the valuation status for TCRR stock?

ChartMill assigns a valuation rating of 3 / 10 to TCR2 THERAPEUTICS INC (TCRR). This can be considered as Overvalued.


Can you provide the profitability details for TCR2 THERAPEUTICS INC?

TCR2 THERAPEUTICS INC (TCRR) has a profitability rating of 1 / 10.


Can you provide the financial health for TCRR stock?

The financial health rating of TCR2 THERAPEUTICS INC (TCRR) is 3 / 10.